Key points from article :
Repair Biotechnologies is focused on developing drugs for cholesterol and aging-related diseases.
Cholesterol in blood can lead to coronary artery disease, heart attack or stroke.
“The SENS and Repair Biotechnologies....reverse age-related disease by repairing the damage," Reason, Co-Founder and CEO of Repair Bio.
“CDP strikes at a root cause of atherosclerosis and other conditions in which excess cholesterol drives pathology."
Degrading excess cholesterol with an entirely new, target-specific and rate-limited pathway.
“Introduced into mice, the CDP pathway is safe and well-tolerated.”
Repair Bio is planning for human trials in 2022.
“Our early trials will be small and focused on safety rather than efficacy."
“...will be treated with CDP in conjunction with statins or similar cholesterol-lowering drugs."
“The endgame is a low-cost mass-produced therapy that one takes every few years beginning in the 40s or 50s.."
Goal is to provide this new treatment to every middle-aged person in the world.
